1.KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis.
Eui Yeun YI ; Shi Young PARK ; Hyun Seok SONG ; Myung Jin SON ; Kyu Yang YI ; Sung En YOO ; Yung Jin KIM
Experimental & Molecular Medicine 2006;38(5):502-508
Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angiogenesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new benzopyran derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogenesis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.
Vascular Endothelial Growth Factor Receptor-2/metabolism
;
Receptor, Fibroblast Growth Factor, Type 2/metabolism
;
Neovascularization, Physiologic/drug effects
;
Neovascularization, Pathologic/*drug therapy
;
Models, Biological
;
Mice, Inbred C57BL
;
Mice
;
Matrix Metalloproteinase 2/metabolism
;
Male
;
Ischemia/drug therapy
;
Imidazoles/*pharmacology/therapeutic use
;
Fibroblast Growth Factor 2/metabolism
;
Endothelial Cells/drug effects
;
Cells, Cultured
;
Cell Movement/drug effects
;
Cattle
;
Benzopyrans/*pharmacology/therapeutic use
;
Animals
;
Angiogenesis Inhibitors/*pharmacology/therapeutic use
2.A Case With Suspected Tick Paralysis.
Hyun Ui LEE ; Seok Beom KWON ; Yun Jung HONG ; Yung En KIM ; Yang Ki MINN ; Soo Jin CHO ; Ki Han KWON
Journal of the Korean Neurological Association 2008;26(3):277-280
Tick paralysis is caused by a neurotoxin secreted by female tick. Characteristic initial manifestation is bilateral flaccid ascending paralysis similar to Guillain-Barr? syndrome. The predominant electrophysiological abnormality is a reduction in complex muscle action potentials. Here, we present a 62-year-old man who initially experienced a sudden biting pain on his scalp. Subsequently he developed bilateral lower extremity paralysis that ascended symmetrically involving the upper extremities. Within 2 weeks, the patient showed a full recovery without treatment.
Action Potentials
;
Bites and Stings
;
Female
;
Humans
;
Lower Extremity
;
Middle Aged
;
Muscles
;
Paralysis
;
Scalp
;
Tick Paralysis
;
Ticks
;
Upper Extremity